XLON
POLB
Market cap26mUSD
Jul 29, Last price
2.65GBP
1D
-5.36%
1Q
-19.70%
IPO
-75.06%
Name
Poolbeg Pharma PLC
Chart & Performance
Profile
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY |
---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | |
Income | |||
Revenues | |||
Cost of revenue | 5,079 | 5,290 | |
Unusual Expense (Income) | |||
NOPBT | (5,079) | (5,290) | |
NOPBT Margin | |||
Operating Taxes | (574) | (91) | |
Tax Rate | |||
NOPAT | (4,505) | (5,199) | |
Net income | (3,931) -16.11% | (4,686) 100.60% | |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | (12,171) | (16,193) | |
Cash flow | |||
Cash from operating activities | (3,847) | (4,368) | |
CAPEX | (597) | ||
Cash from investing activities | 359 | (388) | |
Cash from financing activities | |||
FCF | (4,898) | (5,131) | |
Balance | |||
Cash | 12,171 | 16,193 | |
Long term investments | |||
Excess cash | 12,171 | 16,193 | |
Stockholders' equity | (10,113) | (6,922) | |
Invested Capital | 24,555 | 25,199 | |
ROIC | |||
ROCE | |||
EV | |||
Common stock shares outstanding | 500 | 500,000 | |
Price | |||
Market cap | |||
EV | |||
EBITDA | (5,053) | (5,264) | |
EV/EBITDA | |||
Interest | |||
Interest/NOPBT |